Summary
Benzbromarone is one of the main uricosuric drugs currently used. We determined plasma concentrations of benzbromarone, bromobenzarone, and benzarone and 24 hour uric acid excretion in ten healthy individuals following fasting application of two different non-micronised benzbromarone brands. In addition we explored the influence of adjusting urinary pH to near neutral values and of concomitant food intake. Benzbromarone was more rapidly absorbed from the test preparation than from the reference preparation; the extent of systemic availability did not differ significantly. Urinary pH adjustment had no clearcut effect, whereas food intake retarded drug absorption (even though not significant because of the variability of the data). Binding of benzbromarone to plasma proteins exceeded 99%. Bromobenzarone and benzarone were not detectable and are unlikely to be major metabolites of benzbromarone. Instead we found two other compounds suggestive of metabolites, one of them being monohydroxilated benzbromarone. The plasma concentrations of the parent compound in one subject exceeded those of the rest of the group, possibly indicating genetic differences in drug metabolism. The uricosuric effect was not related to benzbromarone plasma concentrations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AUC:
-
area under the (plasma concentration time) curve
- GC-MS:
-
gas chromatography-mass spectrometry
- HPLC:
-
high performance liquid chromatography
- t1/2:
-
plasma elimination half life
References
Broekhuysen J, Pacco M, Sion R, Demeulenaere L, van Hee M (1972) Metabolism of benzbromarone in man. Eur J Clin Pharmacol 4:125–130
Delbarre F, Auscher C, Olivier JL, Rose A (1967) Traitement des hyperuricémies et la goutte par des dérivés du benzofurannes. Sem Hop Paris 43:1127–1133
Ferber H, Vergin H, Hitzenberger G (1981) Pharmacokinetics and biotransformation of benzbromarone in man. Eur J Clin Pharmacol 19:431–435
Gröbner W, Zöllner N (1977) Harnsäuresteine und Ernährung. Akt Ernährung 3:82–85
Hartung R (1985) Urolithiasis: Prophylaxe und Metaphylaxe. Dtsch Ärztebl 82:40–42
Heel RC, Brodgen RN, Speight TM, Avery GS (1977) Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricemia. Drugs 14:349–366
Jacobsen FK, Christensen CK, Mogensen CE, Andreasen F, Heilskov NS (1979) Pronounced increase in serum creatinine concentration after eating cooked meat. Br Med J I:1049–1050
Klingeberg J (1972) Die Beeinflussung der aktuellen Harnreaktion durch verschiedene Getränke im Rahmen der Harnsteintherapie und -prophylaxe. Urologe (Ausg. B) 12:155–157
Löffler W (1986) Ernährungstherapie der Hyperurikämie — Wissenschaftliche Grundlagen und praktische Konsequenzen. Verh Dtsch Ges Inn Med 92:484–492
Matzkies F, Berg G (1977) Zur Wirkung von 100 mg und 50 mg Benzbromaron bei Gesunden. Fortschr Med 95:1745–1750
Samberger N, Braun J, Lux B, May P (1979) Harnsäuresteinbildung und Uratverstopfung der ableitenden Harnwege durch Urikosurika. Akt Urologie 10:21–27
SAS Institute Inc. (1986) SAS/STAT Guide for personal computers. Cary, NC, USA; Version 6; pp 57–82
Staehler W, Völter D, Ziegler H, Braun WD (1974) Die Urolithiasis. Med Welt 25:1–7
de Vries JX, Voelker U (1987) The binding of the coumarin anticoagulant phenprocoumon and its metabolites to human plasma proteins; its determination by ultrafiltration and HPLC. Proc 7th Steenbock symposium “Current advances in vitamin K research” (in press)
de Vries JX, Walter-Sack I, Ittensohn A (1986) Analysis of benzbromarone and its metabolites in human plasma and urine by HPLC and GC-MS. Naunyn-Schmiedeberg's Arch Pharmacol 334, Suppl.: R 56
de Vries JX, Walter-Sack I, Ittensohn A (1987) Analysis of benzbromarone in human plasma and urine by high — performance liquid chromatography and gas chromatography — mass spectrometry. J Chromatogr 417:420–427
de Vries JX, Walter-Sack I, Löffler W (1987) The biotransformation of benzbromarone in humans. Characterisation of a new metabolite by gas chromatography mass spectrometry. Klin Wochenschr 65, Suppl X:10
Walter-Sack I, de Vries JX, Ittensohn A, Weber E (1987) Benzbromarone disposition following single dose application. Evidence for lack of debromination. Klin Wochenschr 65 (Suppl X):5
Yü T-F (1976) Pharmacokinetic and clinical studies of a new uricosuric agent — benzbromarone. J Rheumatol 3:305–312
Zöllner N, Dofel W, Gröbner W (1970) Die Wirkung von Brenzbromaronum auf die renale Harnsäureausscheidung Gesunder. Klin Wochenschr 48:426–432
Zöllner N, Griebsch A, Fink JK (1970) Über die Wirkung von Benzbromaron auf den Serumharnsäurespiegel und die Harnsäureausscheidung des Gichtkranken. Dtsch med Wochenschr 95:2405–2412
Author information
Authors and Affiliations
Additional information
Dedicated to Professor Dr. N. Zöllner on the occasion of his 65th anniversary
Rights and permissions
About this article
Cite this article
Walter-Sack, I., de Vries, J.X., Ittensohn, A. et al. Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone. Klin Wochenschr 66, 160–166 (1988). https://doi.org/10.1007/BF01727785
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01727785